Juvenile arthritis is a group of autoimmune conditions that cause joint inflammation in children under 18. An estimated 220,000 children and adolescents in the United States have a diagnosed form of the disease, and prevalence rises sharply with age: roughly 77 per 100,000 children under 6, climbing to 592 per 100,000 among those aged 12 to 17.
The formal medical term is juvenile idiopathic arthritis (JIA), meaning the cause is unknown. Unlike a sprained ankle or growing pains, JIA involves the immune system attacking healthy joint tissue, producing chronic swelling, stiffness, and pain that can last months, years, or into adulthood.
Why the Immune System Attacks the Joints
In most subtypes of JIA, the core problem is a malfunction in the body’s adaptive immune system. Certain immune cells that normally fight infections become overactive and produce inflammatory signals that damage the lining of the joints. One key signal, a protein called IL-17, triggers the release of enzymes that break down cartilage and bone. This is the main driver of joint damage in the most common forms of the disease.
Systemic JIA, the subtype that affects the whole body, works differently. Instead of the adaptive immune system going haywire, it’s the innate immune system (the body’s first-response defense) that stays persistently switched on. Immune cells like macrophages and neutrophils flood the body with inflammatory proteins, causing high fevers and organ inflammation alongside joint symptoms.
No one knows exactly what triggers this immune dysfunction. It likely involves a combination of genetic susceptibility and environmental factors, though no single gene or exposure has been identified as a definitive cause.
The Seven Types of JIA
JIA is not a single disease. The international classification system recognizes seven distinct subtypes, each defined by the number of joints involved, blood test results, and the presence of symptoms outside the joints.
- Oligoarthritis affects one to four joints in the first six months and is the most common subtype. It can stay limited (persistent) or eventually spread to more than four joints (extended).
- Rheumatoid factor-negative polyarthritis involves five or more joints but tests negative for a blood marker called rheumatoid factor.
- Rheumatoid factor-positive polyarthritis also involves five or more joints but tests positive for rheumatoid factor on at least two occasions. This form closely resembles adult rheumatoid arthritis.
- Systemic arthritis includes joint inflammation plus a daily spiking fever lasting at least two weeks, often accompanied by a salmon-colored rash, swollen lymph nodes, or enlarged liver or spleen.
- Psoriatic arthritis combines joint inflammation with the skin condition psoriasis, or with features like swollen fingers/toes and nail changes.
- Enthesitis-related arthritis involves inflammation where tendons and ligaments attach to bone, particularly around the hips, knees, and lower back. It’s linked to a genetic marker called HLA-B27 and is more common in boys over age six.
- Undifferentiated arthritis is the classification for cases that don’t fit neatly into one category or that overlap two or more.
Recognizing the Symptoms
The hallmark signs are joint swelling, stiffness (especially in the morning or after sitting still), and pain that persists for weeks rather than days. Young children may not complain about pain directly. Instead, parents often notice a limp, reluctance to use one hand, or a child who seems unusually stiff after naps.
Systemic JIA stands apart because it produces high, recurring fevers and a rash that comes and goes, sometimes before any joint symptoms appear. Other subtypes can cause fatigue, reduced appetite, and irritability that might initially be mistaken for other childhood illnesses.
How JIA Is Diagnosed
There is no single test that confirms JIA. Diagnosis depends on a child having persistent joint inflammation for at least six weeks, with other causes (like infection or injury) ruled out. Blood work helps classify the subtype rather than confirm the disease itself.
The most commonly ordered markers include antinuclear antibody (ANA), which is found in many children with JIA but can also be positive in healthy kids. Rheumatoid factor and anti-CCP antibodies are rarely detected in children with JIA, and when present, they typically point to the rheumatoid factor-positive polyarthritis subtype. HLA-B27, a genetic marker, is associated with enthesitis-related JIA but doesn’t guarantee the disease will develop.
Doctors also use imaging, particularly ultrasound and MRI, to detect early joint inflammation that may not yet be visible on a standard X-ray.
Eye Inflammation Is a Serious Risk
One of the most important complications of JIA has nothing to do with joints. Chronic inflammation of the eye, called uveitis, can develop silently, without redness or pain, and lead to vision loss if undetected. Children with oligoarthritis who test positive for ANA are at the highest risk.
Current guidelines from the American College of Rheumatology recommend eye exams by an ophthalmologist every three months for high-risk children. Even when uveitis is controlled, monitoring continues at least every three months while on stable treatment. Any time medications are being tapered or changed, an eye check within one to two months is strongly recommended. These screenings are a non-negotiable part of JIA care.
Effects on Growth and Development
Chronic inflammation can interfere with a child’s growth in several ways. The inflammatory proteins circulating in the body, particularly IL-6 in systemic JIA, suppress growth hormone activity. One study of children with early JIA found that 39% experienced measurable growth restriction within the first years of disease.
Certain medications compound the problem. Long-term use of oral corticosteroids has been linked to reduced final adult height because these drugs interfere with growth hormone at multiple levels. Poor appetite, whether from the disease itself or from side effects of treatments like methotrexate, can also contribute.
Inflammation near a growth plate can cause that limb to grow faster or slower than its counterpart, potentially creating a leg-length difference. While initially reversible with good disease control, long-standing growth impairment can become permanent, affecting both physical stature and body composition into adulthood.
Treatment Options
The goal of treatment is to eliminate active inflammation, not just manage pain. Achieving this early gives children the best chance of normal joint development and long-term function.
Most children start with anti-inflammatory medications. If those aren’t enough, a class of drugs called disease-modifying agents (methotrexate is the most widely used) works to slow the immune system’s attack on the joints. Methotrexate is typically given once a week, either as a pill or injection, and can take several weeks to reach full effect.
The biggest shift in JIA treatment over the past two decades has been biologic therapies. These are targeted medications delivered by injection or infusion that block specific inflammatory proteins. The main categories include drugs that block TNF (a protein driving joint destruction), drugs that block IL-1 (central to systemic JIA’s fevers and inflammation), and drugs that block IL-6 (which contributes to both inflammation and growth suppression). Other biologics work by calming overactive immune cells directly. Biologics have dramatically improved outcomes for children who don’t respond to older treatments.
Exercise and Physical Therapy
Staying physically active is one of the most important things a child with JIA can do. Research supports several specific activities: Pilates has the strongest evidence for improving quality of life, pain levels, physical function, and range of motion. Aquatic exercise (pool-based aerobic workouts) reduces the number of actively inflamed joints while being gentle on them. Home exercise programs designed by a physical therapist also improve function and quality of life.
The instinct to rest inflamed joints is understandable, but prolonged inactivity leads to muscle weakness and joint stiffness that makes the disease harder to manage. Physical therapy focuses on maintaining full range of motion, building strength around vulnerable joints, and keeping kids participating in the activities that matter to them.
Long-Term Outlook
JIA is not something children simply outgrow. In one large Nordic study tracking 423 children over time, roughly 60% had not achieved medication-free remission by their final follow-up visit. Many of these children carry the disease into adulthood and require ongoing treatment.
That said, outcomes have improved significantly with modern therapies. Children diagnosed today have access to biologic medications that weren’t available a generation ago, and early, aggressive treatment can prevent much of the joint damage that older approaches couldn’t avoid. The subtypes with the best prognosis tend to be persistent oligoarthritis (fewer joints involved, often responding well to treatment) while systemic and rheumatoid factor-positive polyarthritis generally require more intensive management.